Burzynski Research Institute announced that it has signed a Research Agreement with the University of Alabama at Birmingham, Division of Preventive Medicine, Biostatistics and Bioinformatics Shared Facility (BBSF) that will provide biostatistical and data management support for BRI's ongoing Phase II and Phase III protocol studies of Antineoplaston (ANP) treatment for gliomas. The BBSF has the experience and capacity to assist BRI with developing statistical analysis plans; database design; data receipt, management, and long term storage; implementation of quality assurance plans; and the generation of data quality, and study outcome data reports for scientific presentations, publications, and reports. The BBSF is continuing to develop new statistical methodologies, new information technology and approaches to databases, new approaches to quality assurance programs, more efficient procedures for incorporating the results of statistical analyses into reports, presentations and publications, and more efficient and cost effective systems for long term data storage, backup, and retrieval.

Burzynski Research Institute reported earnings results for the first quarter ended May 31, 2009. For the quarter, the company reported net loss of $1.12 million, up from $1.28 million for the same quarter a year ago.

Burzynski Research Institute announced that on May 18, 2009, Fitts, Roberts & Co., P.C. resigned as the independent auditor for the company. Concurrently, the Board of Directors of the company accepted the resignation of Fitts Roberts and approved the appointment of Pannell Kerr Forster of Texas, P.C. as the company’s new independent auditor.